GlassScriptPhysician profile
Nimi P Patel
NPI 1235410911
$5,527.34
in general payments reported to CMS, 2019-2025
46 companies · $1,524 in 2025
The $1,524 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $302 · 2021: $321 · 2022: $646 · 2023: $1,162 · 2024: $1,271 · 2025: $1,524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,744 · Education: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,743.94 |
| Education | $212.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $756.25 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $601.51 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Pfizer INC. | $597.24 | 2019-2025 | |
| Ucb, INC. | $354.38 | 2019-2025 | Rystiggo, Zilbrysq, Fintepla |
| Alexion Pharmaceuticals, INC. | $238.89 | 2022-2025 | Ultomiris |
| Argenx US, INC. | $232.65 | 2024-2025 | Vyvgart Hytrulo |
| Neurocrine Biosciences, INC. | $214.41 | 2022-2025 | Ingrezza, Ongentys |
| Genentech USA, INC. | $198.96 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Evrysdi |
| Amgen INC. | $165.30 | 2019-2022 | |
| Livanova USA, INC. | $156.97 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Harmony Biosciences LLC | $137.70 | 2020-2024 | |
| Lundbeck LLC | $137.32 | 2024-2025 | Vyepti, Rexulti |
| Csl Behring | $124.68 | 2020-2025 | Hizentra |
| Otsuka America Pharmaceutical, INC. | $119.42 | 2024-2025 | Rexulti |
| Neurelis, INC. | $115.94 | 2022-2025 | Valtoco |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nimi Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.